8-KLeadership Changes

DEXCOM INC 8-K Report, Executive Changes (Apr 24, 2019)

Filed April 24, 2019For Securities:DXCM

Summary

This 8-K filing from DexCom, Inc. (DXCM) details the approval of a management bonus plan for fiscal year 2019, effective April 18, 2019. This plan is designed to incentivize key management personnel and select individual contributors, including the CEO, CFO, and other named executive officers, by linking cash bonus awards to the achievement of specific financial and performance targets. The plan's structure emphasizes revenue or new patient additions, EBITDA margin, and performance milestones, reflecting a strategic focus on growth and operational efficiency. The bonus payouts are contingent upon meeting predefined thresholds for company-wide performance, with individual performance also playing a role in the final award. The bonus calculation involves a target bonus amount multiplied by a company performance factor and an individual performance factor. Importantly, the maximum payout to any individual is capped at 200% of their target bonus, providing a clear upper limit on compensation for these executive roles. This plan underscores DexCom's commitment to aligning executive compensation with corporate success and shareholder value.

Key Highlights

  • 1DexCom's Board of Directors approved a fiscal year 2019 management bonus plan on April 18, 2019.
  • 2The plan covers the CEO, CFO, other named executive officers, and select contributors.
  • 3Bonus payouts are determined by achieving specified financial and performance targets.
  • 4The bonus calculation is based on target bonus amount, company performance factor, and individual performance factor.
  • 5Maximum payout to any individual is capped at 200% of their target bonus.
  • 6Company performance targets include annual revenue/new patient addition (60%), EBITDA margin (20%), and performance milestones (20%).
  • 7Minimum thresholds must be met for revenue/patient addition and EBITDA margin components to be eligible for payout.

Frequently Asked Questions

The primary purpose of the 2019 management bonus plan is to incentivize and reward DexCom's key management and select employees for achieving specific financial and performance targets, thereby aligning their compensation with the company's overall success and strategic goals.

The bonus amount is calculated by multiplying the individual's target bonus amount (a percentage of their base salary) by a company performance factor and an individual performance factor. The company performance factor is weighted across revenue/new patient additions, EBITDA margin, and performance milestones.

Yes, a minimum annual product/services revenue goal or new patient addition goal and a specified EBITDA margin goal for fiscal 2019 must be met for the respective components of the bonus to be paid. If these minimums are achieved, participants receive 100% of the targeted component, with potential for increased payouts up to 175% for exceeding goals.

The maximum payout to any individual under the bonus plan is capped at 200% of their target bonus amount.